Vycor Medical, Inc., a medical device company with a suite of FDA cleared products, announced today that its wholly-owned subsidiary, NovaVision has launched the first commercial release of its new saccadic eye training therapy which will be marketed in the U.S. as NeuroEyeCoach™. The therapy is now available through the web site www.NeuroEyeCoach.com.
To carry out normal daily tasks, such as finding an object at home or on a supermarket shelf, one needs to make effective eye movements. Unfortunately, normal eye movements are also affected after brain injury making it difficult to integrate visual information and adding to the problems of blindness. Training is needed for patients to learn to make effective use of their eye movement again. NeuroEyeCoach™ has been specifically developed with world-renowned professors in the field to increase the efficiency of eye movement and train the patient to make the most of their remaining vision.
NeuroEyeCoach™ addresses an enormous worldwide market that currently is largely not addressed. It is estimated that in the U.S. alone, there are over 8 million Americans who have suffered a stroke and there are more than 700,000 new stroke cases occurring annually. About 30% of patients with acquired brain injury suffer from visual disorders with stroke being the most frequent cause.
NeuroEyeCoach™ is an innovative program which evolved from Professor Zihl's (a NovaVision Scientific Advisor) extensive research and pioneering of a computer-based saccadic treatment approach which has been the subject of numerous studies. NeuroEyeCoach™ distills all of Professor Zihl's clinical findings into one comprehensive therapeutic product for improving a patient's ability to scan their environment more efficiently.
NeuroEyeCoach™ is the first commercially available saccadic eye training therapy offered via the Internet direct to patients at home. The program is designed to:
Provide meaningful improvement in visual search performance resulting in improvements in navigation skills and object finding. Increase the efficiency of a patient's eye movement and re-train the patient's ability to make most of their remaining vision Be carried out in comfort at home on patient's computer; the program is intuitive and user friendly and has been designed not to be overly taxing and can be completed in 2-4 weeks Have a real positive impact on activities of daily living.
At www.NeuroEyeCoach.com, information can be found on the therapy and patients can register and download the program. The therapy is delivered over the Internet, allowing for the patient to complete the training in the comfort of their home. NeuroEyeCoach™ can also be provided as a clinic-based multi-user device. The device will enable healthcare professionals to provide the therapy to patients under supervision. Alternatively, clinics can use the device to enable patients to try out the therapy while in the clinic. Patients can then be referred to NovaVision for completion of the NeuroEyeCoach™ therapy at home.
Commenting on the announcement, David Cantor, President of Vycor, stated, "We believe today's launch of NeuroEyeCoach™ is a game changer for Vycor. The therapy addresses a very substantial and under-served market. NeuroEyeCoach™ has been designed and developed to meaningfully improve a patient's ability to scan their environment, resulting in a very positive impact on their ability to deal with every day living. We believe there are literally millions of people worldwide who could benefit from this therapy."
Vycor's wholly-owned NovaVision subsidiary is the worldwide leader in the field of neurologically-induced vision loss. In addition to NeuroEyeCoach™, NovaVision markets a non-invasive, computer-based light stimulation therapy called Vision Restoration Therapy (VRT™), which is the only medical device aimed at the restoration of vision for neurologically induced vision loss which has FDA 510 (K) clearance to be marketed in the U.S.
The NeuroEyeCoach™ therapy is highly complementary to VRT™. The two therapies address different visual disabilities each of which results from neurological damage-induced vision loss -- a loss of visual field as well as difficulty with eye movement, affecting the ability to integrate visual information. VRT provides partial restoration of the patient's lost visual field. NeuroEyeCoach™ has been specifically developed to increase the efficiency of eye movement and re-train the patients' ability to integrate visual information between the left and right hand side.
The Company is in parallel actively working on re-engineering its VRT to also enable it for direct to the patient Internet delivery and to streamline a number of business processes related to the delivery and servicing of patients, although the therapy itself will remain unchanged. Once completed, NovaVision plans to offer both NeuroEyeCoach™ and VRT alongside each other in one therapy suite creating the most robust, affordable, Internet-based visual therapy solution targeted at neurologically induced vision loss.
NeuroEyeCoach™ is a result of collaboration between Vycor management, its Chief Scientific Officer Prof. Arash Sahraie, (Chair in Vision Sciences, College of Life Sciences and Medicine at the University of Aberdeen) and Josef Zihl and the rest of its world class NovaVision Scientific Advisory Board.